Publication

ASH •
9 December, 2024 •
•

Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment

Naval Daver, Andrew Danquah, Didier Halimi, Jérôme Wojcik, Emmanuel Monnet

Publication

ASH •
8 December, 2024 •
•

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab as a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W. Leiding, Michael Marrone, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Publication

ACR •
14 November, 2024 •
•

Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Uwe Ullman, Adnan Mahmood, Josefin Blomkvist, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Oral Presentation

Emapalumab in the Treatment of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (mHLH)

Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab as a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials